Next-Generation Sequencing Gene Panels and "Solo" Clinical Exome Sequencing Applied in Structurally Abnormal Fetuses.

Congenital malformations Exome sequencing Fetal genetic analysis Genetic disorder Prenatal diagnosis Single gene disorders

Journal

Fetal diagnosis and therapy
ISSN: 1421-9964
Titre abrégé: Fetal Diagn Ther
Pays: Switzerland
ID NLM: 9107463

Informations de publication

Date de publication:
2021
Historique:
received: 25 05 2021
accepted: 16 08 2021
pubmed: 15 11 2021
medline: 21 12 2021
entrez: 14 11 2021
Statut: ppublish

Résumé

The aim of the study was to assess the diagnostic yield of 2 different next-generation sequencing (NGS) approaches: gene panel and "solo" clinical exome sequencing (solo-CES), in fetuses with structural anomalies and normal chromosomal microarray analysis (CMA), in the absence of a known familial mutation. Gene panels encompassing from 2 to 140 genes, were applied mainly in persistent nuchal fold/fetal hydrops and in large hyperechogenic kidneys. Solo-CES, which entails sequencing the fetus alone and only interpreting the Online Mendelian Inheritance in Man genes, was performed in multisystem or recurrent structural anomalies. During the study period (2015-2020), 153 NGS studies were performed in 148 structurally abnormal fetuses with a normal CMA. The overall diagnostic yield accounted for 35% (53/153) of samples and 36% (53/148) of the fetuses. Diagnostic yield with the gene panels was 31% (15/49), similar to 37% (38/104) in solo-CES. A monogenic disease was established as the underlying cause in 35% of selected fetal structural anomalies by gene panels and solo-CES.

Identifiants

pubmed: 34775388
pii: 000519701
doi: 10.1159/000519701
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

746-756

Informations de copyright

© 2021 The Author(s). Published by S. Karger AG, Basel.

Auteurs

Montse Pauta (M)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), BCNatal, Barcelona, Spain, mpauta@clinic.cat.

Berta Campos (B)

qGenomics. Esplugues de Llobregat, Catalonia, Spain.

Maria Segura-Puimedon (M)

qGenomics. Esplugues de Llobregat, Catalonia, Spain.

Gemma Arca (G)

DepartmentofNeonatology, BCNatal, Hospital Clinic Barcelona, Barcelona, Spain.

Alfons Nadal (A)

Department of Pathology, Hospital Clínic Barcelona, Barcelona, Spain.

Albert Tubau (A)

Department of Obstetrics and Gynecology, Son Llàtzer Hospital, Palma de Mallorca, Spain.

Silvia Pina Perez (SP)

Department of Obstetrics and Gynecology, Parc Taulí Hospital, Sabadell, Catalonia, Spain.

Edda Marimon (E)

Department of Obstetrics and Gynecology, Hospital Sant Joan de Déu, BCNatal, Esplugues de Llobregat, Catalonia, Spain.

Lourdes Martín (L)

Department of Obstetrics and Gynecology, Hospital Joan XXIII de Tarragona, Catalonia, Spain.

Eva López-Quesada (E)

Department of Obstetrics and Gynecology, Hospital Mútua de Terrassa, Terrassa, Spain.

Joan Sabrià (J)

Department of Obstetrics and Gynecology, Hospital Sant Joan de Déu, BCNatal, Esplugues de Llobregat, Catalonia, Spain.

Begoña Muñoz (B)

Department of Obstetrics and Gynecology, Hospital Sant Joan de Reus, Reus, Spain.

Esperanza Garcia (E)

Department of Obstetrics and Gynecology, Hospital Consorci Sanitari de Terrassa, Terrassa, Spain.

Fernanda Paz Y Miño (F)

Department of Obstetrics and Gynecology, BCNatal, Hospital Clínic de Barcelona, Barcelona, Spain.

Virginia Borobio (V)

Department of Obstetrics and Gynecology, BCNatal, Hospital Clínic de Barcelona, Barcelona, Spain.

Olga Gomez (O)

Department of Obstetrics and Gynecology, BCNatal, Hospital Clínic de Barcelona, Barcelona, Spain.

Elisenda Eixarch (E)

Department of Obstetrics and Gynecology, BCNatal, Hospital Clínic de Barcelona, Barcelona, Spain.
Centre for Biomedical Research on Rare Diseases (CIBER-ER), Madrid, Spain.

Monica Lopez (M)

Department of Obstetrics and Gynecology, Hospital Joan XXIII de Tarragona, Catalonia, Spain.

Montserrat Comas Rovira (M)

Department of Obstetrics and Gynecology, Parc Taulí Hospital, Sabadell, Catalonia, Spain.

Antoni Borrell (A)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), BCNatal, Barcelona, Spain.
Department of Obstetrics and Gynecology, BCNatal, Hospital Clínic de Barcelona, Barcelona, Spain.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH